Povidone-Iodine Oral Rinse Study

NCT ID: NCT05239598

Last Updated: 2023-08-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-02-07
• Study Completion Date: 2022-07-13

Brief Summary

This study is a two-arm, randomized, 2-phase study. Phase I will be double blinded clinical trial of the safety and efficacy of an antiseptic mouthwash solution on reducing SARS-CoV-2 load in COVID 19+ adult individuals. Phase II is designed as an open label trial, and all subjects will receive the active mouthwash.

Conditions

COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Povidone-iodine 0.5% antiseptic mouth rinse

Subjects will be asked to rinse/gargle one time with 10 mL of Povidone-iodine 0.5% antiseptic mouth rinse for 30 seconds.

Group Type: EXPERIMENTAL

Mouth rinse

Intervention Type: DRUG

Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.

Placebo

Subjects will be asked to rinse/gargle one time with 10 mL of placebo mouth rinse for 30 seconds.

Group Type: PLACEBO_COMPARATOR

Mouth rinse

Intervention Type: DRUG

Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.

Interventions

Mouth rinse

Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Able and willing to provide informed consent prior to initiation of study procedures.

2. Stated willingness to comply with all study procedures and availability for the duration of the study.

3. Male or female, aged 18 years and older.

4. Clinical diagnosis of COVID-19 infection confirmed with a positive point of care test.

5. Confirmed diagnosis within 5 days of baseline visit (within 5 days of COVID-19 test) and at least one clinical COVID-19 symptom [*Signs and symptoms of COVID-19 present at illness onset vary, but over the course of the disease, most people will experience the following: fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste of smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea.]

6. Presents with a minimum of six natural teeth.

7. Ability to rinse/gargle with study products.

8. Not using mouth rinse/gargling solutions at the time of enrollment.

9. Not taking antimicrobial medications (antibacterial, antiviral, antibiotics, including hydroxychloroquine) at time of enrollment.

10. Ability to participate in the study and come to site during Phase I of the study for collection of swabs and saliva.

11. Willing to use an acceptable method of birth control throughout duration of the study. Acceptable methods include hormonal contraceptives, barrier methods, abstinence, or other effective methods approved by the PI.

12. If continuing to Phase II of the trial, ability to continue using study products for 1 week (+ 3 days). (Participants do not have to agree to participate in Phase II in order to participate in Phase I.)

13. If continuing to Phase II of the trial, agree to receive text messages/phone calls containing questionnaires regarding compliance and use of study product, and reminders, able to complete virtual follow-up study visit for collection of outcomes data.

Exclusion Criteria

1. Individuals receiving antiviral medications

2. Pregnant or breastfeeding women (for premenopausal women of childbearing potential, pregnancy status to be confirmed through a urine pregnancy test during the study visit)

3. Inability to comply with study protocol

4. Having an allergy to any of the study mouthwash ingredients

5. Having any thyroid condition.

6. Presents with a current suspicious oral lesion at the examiner's discretion, and/or currently undergoing radiation therapy for head or neck cancer, and/or has received radiation therapy to the head or neck (including radioactive iodine therapy).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Avrio Health

INDUSTRY

Sponsor Role: collaborator

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Patricia Corby, DDS, MS

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

849386

Identifier Type: -

Identifier Source: org_study_id